AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment strategies.

In December 2024, we received approval to initiate our Phase 1b clinical trial of GT-02287 in people with GBA1 or idiopathic ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and ...

Idiopathic normal pressure hydrocephalus ... vestibular diseases and Parkinson's disease. The differentiation between INPH and Parkinson's disease can be challenging. Both diseases share a ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports.